NCCN Guidelines and Compendium Updated
Flash Update sent October 24, 2012
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Penile Cancer. These NCCN Guidelines® are currently available as Version 1.2013.
- For T1, Grade 3-4 penile cancer tumors, the primary treatment "radiotherapy ± concurrent chemotherapy (category 2B)" was revised to read: "Radiotherapy (category 2B) or Radiotherapy with concurrent chemotherapy (category 3)."
- For T2 or greater penile cancer tumors, the primary treatment "radiotherapy ± concurrent chemotherapy (category 2B)" was clarified as being for "T2 tumors only."
- For the management of enlarged pelvic lymph nodes, "radiotherapy with concurrent chemotherapy" was added as a treatment option.
- The Discussion section was updated to reflect the changes in the algorithm.
For the complete updated versions of the NCCN Guidelines® and the NCCN Drugs and Biologics Compendium (NCCN Compendium®), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.com.
To access free NCCN Guidelines mobile apps for iPhone and Android, visit NCCN.org/mobile.
Now Available! The Virtual Library of NCCN Guidelines are now formatted for iPad. Visit NCCN.org/mobile/tablet.asp.